LPL Financial LLC Raises Stock Holdings in DaVita Inc. $DVA

LPL Financial LLC increased its position in DaVita Inc. (NYSE:DVA) by 36.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,689 shares of the company’s stock after purchasing an additional 4,968 shares during the period. LPL Financial LLC’s holdings in DaVita were worth $2,859,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. grew its stake in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $29,000 after acquiring an additional 76 shares during the last quarter. Copia Wealth Management purchased a new stake in shares of DaVita in the fourth quarter worth $30,000. Coppell Advisory Solutions LLC grew its stake in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock worth $45,000 after acquiring an additional 100 shares during the last quarter. GeoWealth Management LLC grew its stake in shares of DaVita by 30.6% in the fourth quarter. GeoWealth Management LLC now owns 525 shares of the company’s stock worth $79,000 after acquiring an additional 123 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of DaVita by 150.9% in the first quarter. Blue Trust Inc. now owns 567 shares of the company’s stock worth $87,000 after acquiring an additional 341 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DVA. Barclays cut their target price on DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Finally, Truist Financial set a $148.00 price target on DaVita in a report on Friday, August 8th.

DaVita Stock Up 0.7%

DVA stock opened at $135.35 on Monday. DaVita Inc. has a fifty-two week low of $126.07 and a fifty-two week high of $179.60. The business’s 50-day moving average is $139.68 and its two-hundred day moving average is $145.06. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The company has a market cap of $9.68 billion, a price-to-earnings ratio of 13.31, a P/E/G ratio of 0.97 and a beta of 1.09.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. The business had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%. The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.00 earnings per share. As a group, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Insider Activity

In other DaVita news, insider James O. Hearty sold 2,351 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares in the company, valued at $3,905,700. This trade represents a 8.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.50% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.